Command Palette

Search for a command to run...

Clinical Trials · NCT05459285

A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

CompletedPhase 1Dulaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Sunshine Lake Pharma Co., Ltd.
Enrollment
68
Start date
May 2022
Locations
1 site, China
Primary endpoint
Maximum (peak) plasma drug concentration(Cmax)
View Dulaglutide compound reference